Rural Medical Partners at Fallon Medical Center, Baker, Montana.
University of Arizona, Tucson.
JAMA Netw Open. 2019 May 3;2(5):e193755. doi: 10.1001/jamanetworkopen.2019.3755.
Thyroid hormones have been shown to affect several important pathways in cancer development, including colorectal cancer (CRC). Clinical studies examining the association between thyroid disorders and colorectal cancer have conflicting results and have predominantly involved white populations.
To determine if a diagnosis of hyperthyroidism or hypothyroidism is associated with the risk of developing colorectal cancer in an East Asian population.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based case-control study was conducted from April 27, 2018, to November 8, 2018, using the Taiwanese National Health Insurance Research Database. Participants were adults (n = 139 426) either with a new diagnosis (between 2008 and 2013) of primary colorectal cancer without a history of cancer, or without cancer. Cases and controls were matched 1:1 by age, sex, and index date. Diagnosis of hyperthyroidism or hypothyroidism prior to the diagnosis of colorectal cancer (or the same index date in controls) was then determined.
Risk differences in developing colorectal cancer among patients with a medical history of hyperthyroidism or hypothyroidism.
A total of 139 426 patients were included in the study, and 69 713 individuals made up each case and control group, which were both predominantly male (39 872 [57.2%]). The mean (SD) age for those with CRC was 65.8 (13.7) years and for those without CRC was 66.0 (13.6) years. Both hyperthyroidism (adjusted odds ratio [aOR], 0.77; 95% CI, 0.69-0.86; P < .001) and hypothyroidism (aOR, 0.78; 95% CI, 0.65-0.94; P = .008) were associated with a decreased risk of being diagnosed with colorectal cancer. An inverse association of rectal cancer was found among patients aged 50 years or older with a history of hypothyroidism despite treatment (aOR, 0.54; 95% CI, 0.39-0.74; P < .001). A history of hyperthyroidism in all age groups was associated with a lower risk of colon cancer (aOR, 0.74; 95% CI, 0.64-0.85; P < .001), with a stronger association seen among those younger than 50 years (aOR, 0.55; 95% CI, 0.36-0.85; P = .007).
In this study, hypothyroidism appeared to be associated with a lower risk of rectal cancer, whereas hyperthyroidism appeared to be associated with a lower risk of colon cancer. Because of this, biochemical in vivo research and epidemiologic studies appear to be needed to further clarify the nature of these associations.
甲状腺激素已被证明会影响癌症发展的几个重要途径,包括结直肠癌(CRC)。研究甲状腺疾病与结直肠癌之间关联的临床研究结果存在冲突,且主要涉及白种人群。
确定在东亚人群中,甲状腺功能亢进或甲状腺功能减退的诊断是否与结直肠癌的发病风险相关。
设计、设置和参与者:这是一项基于全国人群的病例对照研究,于 2018 年 4 月 27 日至 2018 年 11 月 8 日期间使用台湾全民健康保险研究数据库进行。参与者为成年人(n=139426),要么患有原发性结直肠癌(2008 年至 2013 年间确诊,且无癌症病史),要么没有癌症。病例和对照按年龄、性别和索引日期 1:1 匹配。然后确定在结直肠癌诊断(或对照中的相同索引日期)之前是否存在甲状腺功能亢进或甲状腺功能减退的诊断。
有甲状腺功能亢进或甲状腺功能减退病史的患者发生结直肠癌的风险差异。
共有 139426 名患者纳入研究,每组各有 69713 名患者,两组均以男性为主(39872[57.2%])。CRC 患者的平均(SD)年龄为 65.8(13.7)岁,无 CRC 患者的平均年龄为 66.0(13.6)岁。甲状腺功能亢进(调整后的优势比[aOR],0.77;95%CI,0.69-0.86;P<0.001)和甲状腺功能减退(aOR,0.78;95%CI,0.65-0.94;P=0.008)均与结直肠癌的发病风险降低相关。尽管接受了治疗,但年龄在 50 岁及以上的甲状腺功能减退症患者发生直肠癌的风险呈下降趋势(aOR,0.54;95%CI,0.39-0.74;P<0.001)。所有年龄组的甲状腺功能亢进症病史与结肠癌风险降低相关(aOR,0.74;95%CI,0.64-0.85;P<0.001),50 岁以下人群的相关性更强(aOR,0.55;95%CI,0.36-0.85;P=0.007)。
在这项研究中,甲状腺功能减退似乎与直肠癌风险降低相关,而甲状腺功能亢进似乎与结肠癌风险降低相关。因此,似乎需要进行生化体内研究和流行病学研究,以进一步阐明这些关联的性质。